openPR Logo
Press release

Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights | DelveInsight

12-20-2022 05:37 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Metastatic Castration-Resistant Prostate Cancer Clinical

DelveInsight's, "Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2022," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Metastatic Castration-Resistant Prostate Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Metastatic Castration-Resistant Prostate Cancer clinical trials, NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration Resistant Prostate cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report

• DelveInsight's metastatic castration-resistant prostate cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for metastatic castration-resistant prostate cancer treatment.
• The leading Metastatic castration-resistant prostate cancer companies include AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen, Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, and others are developing novel drug candidates to improve the metastatic castration-resistant prostate cancer treatment landscape.
• Promising Metastatic castration-resistant prostate cancer therapies in the pipeline and are in various stages of development include Capivasertib, TAVT-45, HC-1119, PNT2002, Cabozantinib, TAVT-45, ZEN-3694, SRF 617, PLX2853, REGN5678, VERU-100, CPI-1205, NOX66, IMU-935, AC176, HP518, NZV930, NIR178, NUV 422, XL092, VERU-111, BAY2315497, Onvansertib, Enfortumab vedotin, Talazoparib, and others.
• The Metastatic castration-resistant prostate cancer Companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Castration Resistant Prostate cancer. The Metastatic castration-resistant prostate cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Castration Resistant Prostate cancer.

Request a sample and discover the recent breakthroughs and advances in metastatic castration-resistant prostate cancer drug treatment and get a snapshot of the Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Castration-Resistant Prostate Cancer Overview

Prostate cancer is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named "hormone-refractory prostate cancer" and "androgen-independent prostate cancer". However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.

Recent Developmental Activities in the Metastatic Castration-Resistant Prostate Cancer Treatment Landscape

• In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) had been successfully dosed in Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.
• In December 2021, Accutar Biotechnology announced the FDA clearance of the IND application for Phase I Trial of AC0176 in prostate cancer. Accutar expects to begin enrollment in Phase 1 clinical trial for AC0176 in the first quarter of 2022.
• In April 2022, Janssen announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet plus prednisone, based on the results of the Phase III MAGNITUDE study for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR) gene alterations. In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer.
• In May 2022, Janux Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Company's investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). JANX007 is the Company's lead novel T cell engager (TCE) therapeutic from its TRACTr platform. Janux plans to initiate a Phase I clinical trial for JANX007 in the second half of 2022.
• In June 2022, Blue Earth Therapeutics announced results from a series of preclinical analyses designed to evaluate the biodistribution and potential therapeutic efficacy of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in the treatment of prostate cancer preclinical models. In April 2022, the FDA cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC).
• Oncternal is supporting an investigator-sponsored study being conducted at the UC San Diego School of Medicine, a Phase Ib clinical trial of zilovertamab in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC). In addition, it is also developing ONCT-534, a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration-resistant prostate cancers, including those with clinically important resistance to approved androgen receptor inhibitors.
• In June 2022, ESSA Pharma Inc. presented clinical results from the Phase Ia dose-escalation study of EPI-7386, ESSA's first-in-class N-terminal domain androgen receptor inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer resistant to current standard-of-care therapies. The initial data from 36 patients demonstrated that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. ESSA expects to initiate the Phase Ib expansion study in Q3 2022.
• In May 2022, Arcus Biosciences reported that data analysis from the randomized cohort of ARC-6 evaluating etrumadenant plus zimberelimab and docetaxel versus docetaxel in second-line metastatic castrate-resistant prostate cancer (CRPC) is anticipated in the second half of 2022 with a presentation of results expected in 2023.
• In February 2022, Arvinas reported that the novel androgen receptor (AR) PROTAC degrader, bavdegalutamide (ARV-110), was found to be clinically active and tolerable with manageable adverse effects (AEs) in Phase I/II clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1 to 2 prior novel hormonal drugs.
• In March 2022, Forma therapeutics reported positive results from Phase I clinical trial evaluating FT-7051. It was well tolerated with signs of clinical activity and continues to enroll men with metastatic castration-resistant prostate cancer (mCRPC). The first evaluable patient completing 12 weeks of treatment demonstrated a >80% decline in prostate-specific antigen (PSA80) from baseline at 16 weeks with stable disease. As of May 2022, 25 patients were enrolled in the Phase I dose-escalation trial, assessing the predicted efficacious exposure range supported by target engagement. Future trial enrollment to include less heavily pre-treated patients and alternative dosing schedules to address adverse events, with updated results expected in the first half of 2023.

Metastatic Castration Resistant Prostate cancer Emerging Drugs

SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.

Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.

HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.

Metastatic Castration Resistant Prostate cancer Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.

Learn more about the novel and emerging metastatic castration-resistant prostate cancer therapies and Metastatic Castration-Resistant Prostate Cancer Clinical Trials @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Castration-Resistant Prostate cancer Pipeline Report

• Coverage- Global
• Metastatic Castration-Resistant Prostate Cancer Companies: AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen, Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, and others
• Key Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies: Capivasertib, TAVT-45, HC-1119, PNT2002, Cabozantinib, TAVT-45, ZEN-3694, SRF 617, PLX2853, REGN5678, VERU-100, CPI-1205, NOX66, IMU-935, AC176, HP518, NZV930, NIR178, NUV 422, XL092, VERU-111, BAY2315497, Onvansertib, Enfortumab vedotin, Talazoparib, and others.
• Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment: Phases, Product Type, Molecule Type, Route of Administration

Dive deep into rich insights into new metastatic castration-resistant prostate cancer treatment drugs and Metastatic Castration-Resistant Prostate Cancer Drug Treatment Guidelines, visit @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Metastatic Castration Resistant Prostate cancer Executive Summary
3. Metastatic Castration Resistant Prostate cancer: Overview
4. Metastatic Castration Resistant Prostate cancer Pipeline Therapeutics
5. Metastatic Castration Resistant Prostate cancer Therapeutic Assessment
6. Metastatic Castration Resistant Prostate cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Clovis Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Surface Oncology: SRF 617
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. REGN 4336: Regeneron Pharamceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. HP 518: Hinova Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Castration Resistant Prostate cancer Key Companies
21. Metastatic Castration Resistant Prostate cancer Key Products
22. Metastatic Castration Resistant Prostate cancer- Unmet Needs
23. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
24. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
25. Metastatic Castration Resistant Prostate cancer Analyst Views
26. Metastatic Castration Resistant Prostate cancer Key Companies
27. Appendix

For further information on the metastatic castration-resistant prostate cancer pipeline therapeutics and Metastatic Castration-Resistant Prostate Cancer Drugs, reach out @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Clinical Trial Pipeline Insights | DelveInsight here

News-ID: 2855937 • Views:

More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market. The Spinocerebellar
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics. DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,
Myocardial Infarction Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Metastatic

Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025? The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034? The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market? The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth? The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size? The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer. Download Report: https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control